Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raymond Hupperts

Showing results (91-100 of 115) with videos related to

Pageof 12
Sort By:
Journal of Neurology, Neurosurgery, and Psychiatry|September 30, 2016
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosisNathaniel Lizak, Alessandra Lugaresi, Raed Alroughani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 7, 2014
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosisTomas Kalincik, Vilija Jokubaitis, Guillermo Izquierdo, et al.
The Lancet. Neurology|March 22, 2020
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort studyAnna He, Bernd Merkel, James William L Brown, et al.
Brain : a Journal of Neurology|September 12, 2015
Defining reliable disability outcomes in multiple sclerosisTomas Kalincik, Gary Cutter, Tim Spelman, et al.
Annals of Clinical and Translational Neurology|May 23, 2015
Predictors of disability worsening in clinically isolated syndromeVilija G Jokubaitis, Tim Spelman, Tomas Kalincik, et al.
Neurology|October 7, 2020
Treatment Response Score to Glatiramer Acetate or Interferon Beta-1aFrancesca Bovis, Tomas Kalincik, Fred Lublin, et al.
Plos One|June 6, 2015
Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MSKaren Ann Ribbons, Patrick McElduff, Cavit Boz, et al.
JAMA|January 16, 2019
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple SclerosisJ William L Brown, Alasdair Coles, Dana Horakova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 23, 2015
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosisMatthew Warrender-Sparkes, Tim Spelman, Guillermo Izquierdo, et al.
Brain : a Journal of Neurology|May 10, 2020
Early clinical markers of aggressive multiple sclerosisCharles B Malpas, Ali Manouchehrinia, Sifat Sharmin, et al.
Pageof 12

Showing results (91-100 of 115) with videos related to

Sort By:
Pageof 12
Journal of Neurology, Neurosurgery, and Psychiatry|September 30, 2016
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosisNathaniel Lizak, Alessandra Lugaresi, Raed Alroughani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 7, 2014
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosisTomas Kalincik, Vilija Jokubaitis, Guillermo Izquierdo, et al.
The Lancet. Neurology|March 22, 2020
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort studyAnna He, Bernd Merkel, James William L Brown, et al.
Brain : a Journal of Neurology|September 12, 2015
Defining reliable disability outcomes in multiple sclerosisTomas Kalincik, Gary Cutter, Tim Spelman, et al.
Annals of Clinical and Translational Neurology|May 23, 2015
Predictors of disability worsening in clinically isolated syndromeVilija G Jokubaitis, Tim Spelman, Tomas Kalincik, et al.
Neurology|October 7, 2020
Treatment Response Score to Glatiramer Acetate or Interferon Beta-1aFrancesca Bovis, Tomas Kalincik, Fred Lublin, et al.
Plos One|June 6, 2015
Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MSKaren Ann Ribbons, Patrick McElduff, Cavit Boz, et al.
JAMA|January 16, 2019
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple SclerosisJ William L Brown, Alasdair Coles, Dana Horakova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 23, 2015
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosisMatthew Warrender-Sparkes, Tim Spelman, Guillermo Izquierdo, et al.
Brain : a Journal of Neurology|May 10, 2020
Early clinical markers of aggressive multiple sclerosisCharles B Malpas, Ali Manouchehrinia, Sifat Sharmin, et al.
Pageof 12